Research programme: Filovirus immunotherapeutics - GeoVax Labs

Drug Profile

Research programme: Filovirus immunotherapeutics - GeoVax Labs

Alternative Names: GEO EM03; GEO EM05; GEO-EM01; GEO-LM01; GOVX E301; GOVX E302; GOVX-E303; Haemorrhagic fever vaccine - GeoVax; Monovalent vaccine - GeoVax; MVA-VLP Ebola vaccine - GeoVax; MVA-VLP tetravalent vaccine - GeoVax

Latest Information Update: 31 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeoVax Labs
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ebola virus infections; Lassa fever
  • Research Marburg virus disease

Most Recent Events

  • 24 Jul 2017 GeoVax collaborates with the Scripps Research Institute and the University of Maryland Medical School for Lassa fever
  • 11 Jul 2017 Pharmacodynamics data from a preclinical trial in Lassa fever released by GeoVax
  • 01 Jul 2016 Preclinical trials in Lassa fever (Prevention) in USA (Parenteral) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top